Straits Times Index
3,332.44 -10.91 (-0.33%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,755.62 +39.15 (+0.22%) FTSE 100
8,179.68 -45.65 (-0.55%) Bitcoin USD
61,536.71 +893.06 (+1.47%) CMC Crypto 200
1,281.93 -1.90 (-0.15%)
Daiichi Sankyo Co Ltd (D4S.MU)
| Previous close | 32.36 |
| Open | 32.36 |
| Bid | 31.91 x 0 |
| Ask | 32.43 x 0 |
| Day's range | 32.36 - 32.36 |
| 52-week range | 22.86 - 34.20 |
| Volume | |
| Avg. volume | 1 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
- Benzinga
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
On Wednesday, the FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) and Merck & Co Inc’s (NYSE:MRK) patritumab deruxtecan (HER3-DXd) for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies. The CRL results from findings about an inspection of a third-party manufacturing facility. The CRL
- Zacks
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
